Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Neurology

Why is Aicardi-Goutières Misdiagnosed as Cerebral Palsy?

At a Glance

Aicardi-Goutières syndrome (AGS) is often misdiagnosed as cerebral palsy because both cause similar muscle stiffness, movement issues, and white matter brain damage. However, AGS is a progressive genetic disorder marked by skill loss, immune inflammation, and specific brain calcifications.

Many families go through a stressful and confusing “diagnostic odyssey” when their child is initially diagnosed with cerebral palsy (CP), only to learn later that the true cause of their symptoms is Aicardi-Goutières syndrome (AGS). This misdiagnosis happens because the two conditions share nearly identical physical symptoms and show similar patterns of white matter damage on early brain imaging [1]. Cerebral palsy is a relatively common umbrella term for movement disorders caused by a brain injury before or during birth. In contrast, AGS is a rare genetic disorder that causes the body’s immune system to attack its own brain and body tissues. Because CP is much more common, doctors often make this diagnosis first based on outward clinical signs, before advanced genetic testing reveals the underlying autoinflammatory cause of AGS [1][2].

Overlapping Physical Symptoms

To a doctor observing a child’s movements in a clinic, AGS and cerebral palsy can look extremely similar [1]. Both conditions frequently cause:

  • Spasticity: This refers to tight, stiff muscles that can make moving the arms and legs difficult [3][2].
  • Dystonia: These are abnormal, involuntary muscle contractions that lead to repetitive twisting movements or rigid, uncomfortable postures [3].
  • Developmental Delays: Many children face delays in reaching milestones like sitting, crawling, speaking, or walking [3].

Because these physical symptoms are the hallmark of cerebral palsy, many children with AGS are initially grouped into a CP diagnosis, particularly when the exact underlying cause of their neurological impairment is not immediately clear [1].

Similarities on Brain Imaging

The overlap between AGS and CP extends beyond outward physical symptoms to brain imaging. When a child undergoes a magnetic resonance imaging (MRI) scan to investigate developmental delays or muscle stiffness, doctors are looking for structural differences in the brain.

  • White Matter Damage: Both conditions often show white matter damage or abnormalities (leukoencephalopathy) [2][4]. The white matter is the “wiring” that transmits signals throughout the nervous system. In cerebral palsy, this is typically an acquired injury (like periventricular leukomalacia) caused by a lack of oxygen around birth. In AGS, it is a genetic disorder of the white matter called a leukodystrophy [2][4].
  • Brain Atrophy: Both conditions can present with shrinkage (atrophy) of certain brain regions over time [4][3].

Because early MRIs in AGS can mimic the kind of brain changes seen in children with acquired brain injuries, early imaging alone does not always immediately distinguish between the two disorders.

Finding the True Diagnosis: How AGS is Distinguished from CP

While cerebral palsy is historically viewed as a “static” condition (meaning the original injury to the brain does not actively worsen, though physical symptoms like muscle tightness can change as the child grows), AGS is an autoinflammatory disease with periods of active progression [1][5]. Several critical clues eventually lead doctors to the correct AGS diagnosis:

  • Loss of Skills (Regression): Unlike typical CP, children with AGS often experience a subacute phase of neurological deterioration, where they lose developmental skills they had previously acquired [5][6]. While this rapid regression can be frightening, it is often followed by a period of stabilization [6]. Fortunately, emerging therapies are actively being used to help calm the inflammation and aim to protect the child’s brain from further damage during these phases [7][8].
  • Interferon Panels: AGS involves an overactive immune response. Blood and spinal fluid tests can detect an interferon signature—elevated levels of immune proteins (type I interferons) that confirm ongoing inflammation, which is not characteristically present in CP [9][10][11].
  • Intracranial Calcifications: While MRIs are great for detailing white matter, CT scans are better at seeing calcium. Children with AGS typically have distinct calcium deposits (intracranial calcifications) in specific parts of the brain, such as the basal ganglia [12][13].
  • Chilblains: Many children with AGS develop red, swollen, or painful skin lesions on their toes, fingers, and ears (chilblains) during cold weather. This is a key sign of underlying immune system dysfunction [9][14].
  • Genetic Testing: Ultimately, identifying a specific genetic mutation confirms an AGS diagnosis [1][15].

Genetic testing is a vital step because confirming the genetic cause opens the door to targeted medical management, such as the use of JAK inhibitors [7][8]. These medications (often taken daily as a pill or liquid) work by blocking the specific pathways causing the overactive immune response, representing a treatment path that is completely different from the management of standard cerebral palsy.

If you were previously told your child had cerebral palsy of an “unknown origin,” finding the true AGS diagnosis validates that you were right to keep searching for answers. Genetic confirmation helps you build a specialized care team to manage the underlying inflammation, not just the physical symptoms.

Common questions in this guide

Why are Aicardi-Goutières syndrome and cerebral palsy easily confused?
Both conditions cause very similar physical symptoms like tight muscles, involuntary movements, and developmental delays. Early brain imaging for both can also show similar white matter damage, making them hard to distinguish at first.
How can doctors tell the difference between AGS and cerebral palsy?
Unlike cerebral palsy, which is typically a static condition from an early brain injury, AGS often involves a period of losing previously acquired skills. Doctors also use genetic testing, interferon panels, and CT scans to look for specific signs of AGS inflammation.
What are chilblains in Aicardi-Goutières syndrome?
Chilblains are red, swollen, or painful skin lesions that often appear on the toes, fingers, and ears during cold weather. In children with AGS, this is a key sign of underlying immune system dysfunction rather than just a reaction to the cold.
What treatments are available if a cerebral palsy diagnosis changes to AGS?
Confirming an AGS diagnosis through genetic testing opens up entirely new treatment options, such as targeted therapies called JAK inhibitors. These medications work by blocking the specific pathways causing the overactive immune response, which differs completely from standard cerebral palsy management.
When should I ask my doctor about an autoinflammatory condition instead of cerebral palsy?
If your child experiences a sudden or gradual loss of previously acquired skills, unexplained fevers, or if doctors note calcifications on their brain scans, it may warrant further investigation. A pediatric neurogenetics team can help evaluate these signs.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my child's regression in skills and white matter changes, what specific genetic panels should we order to confirm or rule out Aicardi-Goutières syndrome?
  2. 2.What blood or spinal fluid tests, such as an interferon panel, can we perform to look for signs of ongoing inflammation?
  3. 3.Do we need a referral to a pediatric immunologist or a specialized neurogenetics team?
  4. 4.Could my child's current muscle tightness be evaluated in the context of an autoinflammatory condition rather than a static brain injury?
  5. 5.If genetic testing confirms AGS, what is the process and timeline for evaluating if my child is a candidate for targeted therapies like JAK inhibitors?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Genetic Testing Contributes to Diagnosis in Cerebral Palsy: Aicardi-Goutières Syndrome as an Example.

    Beysen D, De Cordt C, Dielman C, et al.

    Frontiers in neurology 2021; (12()):617813 doi:10.3389/fneur.2021.617813.

    PMID: 33967934
  2. 2

    SIGLEC1 (CD169) as a potential diagnostical screening marker for monogenic interferonopathies.

    Orak B, Ngoumou G, Ebstein F, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2021; (32(3)):621-625 doi:10.1111/pai.13400.

    PMID: 33099809
  3. 3

    Diagnosis of Aicardi-Goutières Syndrome in Adults: A Case Series.

    Videira G, Malaquias MJ, Laranjinha I, et al.

    Movement disorders clinical practice 2020; (7(3)):303-307 doi:10.1002/mdc3.12903.

    PMID: 32258229
  4. 4

    Child Neurology: Aicardi-Goutières Syndrome Presenting as Recurrent Ischemic Stroke.

    Kuang SY, Li Y, Yang SL, Han X

    Neurology 2022; (99(9)):393-398 doi:10.1212/WNL.0000000000200952.

    PMID: 35803721
  5. 5

    Subacute Partially Reversible Leukoencephalopathy Expands the Aicardi-Goutières Syndrome Phenotype.

    Peixoto de Barcelos I, Bueno C, S Godoy LF, et al.

    Brain sciences 2023; (13(8)) doi:10.3390/brainsci13081169.

    PMID: 37626525
  6. 6

    Relapsing-remitting clinical course expands the phenotype of Aicardi-Goutières syndrome.

    Lambe J, Murphy OC, Mu W, et al.

    Annals of clinical and translational neurology 2020; (7(2)):254-258 doi:10.1002/acn3.50979.

    PMID: 31920009
  7. 7

    Nucleotide metabolism, leukodystrophies, and CNS pathology.

    Gavazzi F, Gonzalez CD, Arnold K, et al.

    Journal of inherited metabolic disease 2024; (47(5)):860-875 doi:10.1002/jimd.12721.

    PMID: 38421058
  8. 8

    Novel and emerging treatments for Aicardi-Goutières syndrome.

    Tonduti D, Fazzi E, Badolato R, Orcesi S

    Expert review of clinical immunology 2020; (16(2)):189-198 doi:10.1080/1744666X.2019.1707663.

    PMID: 31855085
  9. 9

    Analysis of clinical characteristics of children with Aicardi-Goutieres syndrome in China.

    Wang W, Wang W, He TY, et al.

    World journal of pediatrics : WJP 2022; (18(7)):490-497 doi:10.1007/s12519-022-00545-1.

    PMID: 35551623
  10. 10

    Neonatal detection of Aicardi Goutières Syndrome by increased C26:0 lysophosphatidylcholine and interferon signature on newborn screening blood spots.

    Armangue T, Orsini JJ, Takanohashi A, et al.

    Molecular genetics and metabolism 2017; (122(3)):134-139 doi:10.1016/j.ymgme.2017.07.006.

    PMID: 28739201
  11. 11

    Type I Interferonopathies in Childhood.

    Haşlak F, Kılıç Könte E, Aslan E, et al.

    Balkan medical journal 2023; (40(3)):165-174 doi:10.4274/balkanmedj.galenos.2023.2023-4-78.

    PMID: 37161741
  12. 12

    Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi-Goutières Syndrome, a Type I Interferonopathy.

    Meesilpavikkai K, Dik WA, Schrijver B, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2019; (71(5)):829-831 doi:10.1002/art.40805.

    PMID: 30666809
  13. 13

    Systemic complications of Aicardi Goutières syndrome using real-world data.

    Peixoto de Barcelos I, Jan AK, Modesti N, et al.

    Molecular genetics and metabolism 2024; (143(1-2)):108578 doi:10.1016/j.ymgme.2024.108578.

    PMID: 39332260
  14. 14

    Multiple Autoimmune Disorders in Aicardi-Goutières Syndrome.

    Samanta D, Ramakrishnaiah R, Crary SE, et al.

    Pediatric neurology 2019; (96()):37-39 doi:10.1016/j.pediatrneurol.2019.01.017.

    PMID: 30898416
  15. 15

    Late-Onset Aicardi-Goutières Syndrome: A Characterization of Presenting Clinical Features.

    Piccoli C, Bronner N, Gavazzi F, et al.

    Pediatric neurology 2021; (115()):1-6 doi:10.1016/j.pediatrneurol.2020.10.012.

    PMID: 33307271

This page is for informational purposes only and does not replace professional medical advice. Always consult a pediatric neurologist or geneticist regarding your child's specific diagnosis and treatment plan.

Get notified when new evidence is published on Aicardi-Goutières syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.